EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

Sobrero, Alberto; Maurel, Joan; Fehrenbacher, Louis; Scheithauer, Werner; Abubakr, Yousif; P. Lutz, Manfred; E. Vega-Villegas, M.; Eng, Cathy; Steinhauer, E.U.; Prausová, Jana; Lenz, Heinz‐Josef; Borg, Christophe; Middleton, Gary; Kröning, H.; Luppi, Gabriele; Kisker, O.; Zubel, Angela; Langer, Christiane; Kopit, Justin; A. Burris, Howard

doi:10.1200/jco.2007.13.1193

Public

EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

Published in Journal of Clinical Oncology • Apr 8, 2008

Authors:

Alberto Sobrero

Joan Maurel

Louis Fehrenbacher

Abstract

PURPOSE: To determine whether adding cetuximab to irinotecan prolongs survival in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine and oxaliplatin. PATIENTS AND METHODS: This multicenter, open-label, phase III study randomly assigned 1,298 patients with epid...

Subject

Irinotecan

Medicine

Cetuximab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!